Evidence map›Paper›PMID 41279627›Full record

ArticlebioRxiv : the preprint server for biology2025

S-Equol: A Novel Therapeutic For HIV-1-Associated Gastrointestinal Dysbiosis.

Mason T Rodriguez, Sarah J Olmstead, Kristen A McLaurin, Charles F Mactutus, Rosemarie M Booze

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Mason T RodriguezCognitive and Neural Science Program, Department of Psychology, Barnwell College, 1512 Pendleton Street, University of South Carolina, Columbia, SC 29208.
Sarah J OlmsteadCognitive and Neural Science Program, Department of Psychology, Barnwell College, 1512 Pendleton Street, University of South Carolina, Columbia, SC 29208.
Kristen A McLaurinCognitive and Neural Science Program, Department of Psychology, Barnwell College, 1512 Pendleton Street, University of South Carolina, Columbia, SC 29208.
Charles F MactutusCognitive and Neural Science Program, Department of Psychology, Barnwell College, 1512 Pendleton Street, University of South Carolina, Columbia, SC 29208.
Rosemarie M BoozeCognitive and Neural Science Program, Department of Psychology, Barnwell College, 1512 Pendleton Street, University of South Carolina, Columbia, SC 29208.

Funding

Biomedical-Behavioral Interface: Prevention and Developmental Sciences TrainingT32GM081740 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI PRINZ, RONALD J · 2008 to 2022
$4.5M
Microglial modulation of neurocircuits in HIV/cocaine comorbidityR01DA059310 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Rosemarie M Booze · 2023 to 2026
$2.0M
Neurobiological Mechanisms of Apathy in HANDR01NS100624 · NINDS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BOOZE, ROSEMARIE M, MACTUTUS, CHARLES F. · 2017 to 2021
$1.8M
Executive Function Impairments in HAND and AgingR01AG082539 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Rosemarie M Booze, Charles F. Mactutus · 2024 to 2026
$1.7M
Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and ComorbiditiesR00DA056288 · NIDA · UNIVERSITY OF KENTUCKY · PI Kristen Addie McLaurin · 2024 to 2026
$747k
Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and ComorbiditiesK99DA056288 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI MCLAURIN, KRISTEN ADDIE · 2022 to 2023
$262k
NIA NIH HHS R01 AG082539NIDA NIH HHS K99 DA056288NIDA NIH HHS R00 DA056288NIDA NIH HHS R01 DA059310NIGMS NIH HHS T32 GM081740NINDS NIH HHS R01 NS100624
6 · The paper itself

Abstract

HIV-1 infection affects approximately 38.4 million people around the world. The advent of combination anti-retroviral therapy (cART) has greatly improved the quality of life of infected individuals; however, roughly 50% of these individuals will still experience HIV-1-associated neurocognitive disorders (HAND). Additionally, the gastrointestinal microbiome has been reported to be dysbiotic in HIV-1 infected individuals, regardless of adherence to cART. Current research has pointed to the gut-brain-microbiota axis as a potential target to treat both cognitive deficits and microbial changes. The present study investigated S-Equol (SE) as a potential therapeutic for HAND by modulating the gastrointestinal microbiome. The study included 21 HIV-1 Tg rats and 21 F344 control animals to test the effect 0.2mg SE has on cocaine-maintained responding on a PR schedule of reinforcement. Gastrointestinal microbiome alterations between genotypes were found at the phylum and genus level, regardless of treatment group, and SE treatment had both main effects and interactions with genotype.

Indexed as

DysbiosisGut-Brain-Microbiota AxisHIVHIV-1-Associated Neurocognitive DisordersS-Equol

Identifiers

PMID41279627
PMCPMC12637485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.